Recruiting

Genomic Sequencing

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07829445

Conditions

LBCL

Comprehensive Genomic

Precision Treatment

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Standard of Care (SOC)

Study Details

Brief summary:

To determine whether special laboratory tests, called genomic sequencing, can identify specific subtypes of LBCL and provide information that may help guide treatment decisions.

Conditions

LBCL

Comprehensive Genomic

Precision Treatment

Study ID

NCT07829445

Start date

Sep 29, 2026

Status verified date

Nov, 2026

Completion date

Jun 30, 2029

Anticipated

Primary completion date

Jun 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Eligibility Criteria

  • Age ≥18y
  • Pathology-confirmed diffuse large B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma (HGBL) who are eligible for standard-of-care, full-dose 6 cycles of anthracycline-based treatment
  • Stage 3 or 4 disease by Lugano Criteria
  • Available biopsy sample for BostonGene Tumor Portrait™ test ( for sample preparation)

Exclusion Criteria

  • Known central nervous system (CNS) disease (cases concerning for CNS involvement should be evaluated with MRI and lumbar puncture)
  • Any baseline characteristics that in the opinion of the treating physician would preclude patients from receiving standard-of-care anthracycline-based treatment
  • Participation (or planning to participate) in any therapeutic clinical trials for lymphoma during the planned treatment course. Note, patients who become eligible for other studies based on inadequate response, toxicity to therapy, or other reasons that arise after the initiation of standard therapy on this study are permitted to pursue those alternative trials as appropriate. Participation in other non-therapeutic and/or observational studies are permitted.

Study Design

Enrollment

60 participants

Anticipated

Interventions and Outcome Measures

Arms

ABC Subtype

DZsig Subtype

Other GCB Subtype

Interventions

Standard of Care (SOC)

Standard of care

Primary outcome measure

  • Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts and Locations

Central contacts

Dai Chihara, MD

713-563-4354JMDennison@mdanderson.org

Locations

UT MD Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Dai Chihara, MD

713-563-4354JMDennison@mdanderson.org

Principal Investigator:

Dai Chihara, MD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Nov 3, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-04. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-11-03. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.